Guideline-directed medical and device therapy use in heart failure with reduced ejection fraction: results from the turkiye heart failure (TURK-HF) registry
U Kocabas, I Ergin, C Altin, C Yildiz, M Kaplan, C Turgul, D Inan, F Cakan, S Akdeniz Oskay, B Murat, S Murat, S Gunay Polatkan, H I Tanriseven, F Er, I TengizAbstract
Background and aim
Guideline-directed medical therapy (GDMT) for patients with heart failure (HF) and reduced ejection fraction (HFrEF) remains suboptimal. This study aimed to evaluate the implementation of GDMT in patients with HFrEF.
Methods
The TURK-HF registry is a national, multicenter, observational, prospective, and ongoing registry of unselected patients with HF.
Results
Between January 8, 2025, and December 12, 2025, 697 outpatients with HFrEF (median age, 65 years; 75.9% men) were enrolled at 41 centers in 25 cities. Renin-angiotensin system (RAS) inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium–glucose cotransporter 2 (SGLT2) inhibitors were prescribed to 84.3%, 90.4%, 71.3%, and 48.6% of patients, respectively. The proportions of patients receiving target doses of medications were 15.5%, 16.9 %, and 9.9% for RAS inhibitors, beta-blockers, and MRAs, respectively (Figure 1). Overall, 221 (31.7%) and 268 (38.5 %) patients were treated with triple and quadruple therapies, respectively (Figure 2). Among the study population, 157 (22.5%) received implantable cardioverter–defibrillator therapy, and 27 (3.9%) received cardiac resynchronization therapy.
Conclusion
The TURK-HF registry provides comprehensive real-world data on the implementation of GDMT in patients with HFrEF.Figure 1For image description, please refer to the figure legend and surrounding text.Figure 2For image description, please refer to the figure legend and surrounding text.